Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure

Current Vascular Pharmacology

Volumn 3, Issue 3, 2005, Pages 221-229

  Ungvári, Zoltan ^a   Gupte, Sachin A ^a   Recchia, Fabio A ^a   Bátkai, Sándor ^b   Pacher, Pál ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FP 15; HYDROGEN PEROXIDE; HYDROXYL RADICAL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIPURINOL; PEROXYNITRITE; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; SUPEROXIDE; UBIDECARENONE; UNCLASSIFIED DRUG; XANTHINE; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR;

ACUTE HEART FAILURE; AGING; ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CELL RESPIRATION; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; ENDOTHELIUM LESION; ENZYME INHIBITION; HEART FAILURE; HEART FUNCTION; HUMAN; HYPERTENSION; LEUKOCYTE ACTIVATION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; RESPIRATORY CHAIN; REVIEW; SHOCK;

ANIMALS; CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; HUMANS; NADPH OXIDASE; OXIDATIVE STRESS; POLY(ADP-RIBOSE) POLYMERASES; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; XANTHINE OXIDASE;

EID: 21644460615     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570161054368607     Document Type: Review

References (120)

1. Ferrari R, Guardigli G, Mele D, Percoco GF, Ceconi C, Curello S. Oxidative stress during myocardial ischaemia and heart failure. Curr Pharm Des. 2004; 10(14): 1699-711.
2. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005; 115(3): 500-8.
3. Hare JM, Stamler JS. NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 2005; 115(3): 509-17.
4. Huss JM, Kelly DP. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 2005; 115(3): 547-55.
5. McKinsey TA, Olson EN. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest 2005; 115(3): 538-46.
6. Morita H, Seidman J, Seidman CE. Genetic causes of human heart failure. J Clin Invest 2005; 115(3): 518-26.
7. Pacher P, Schulz R, Liaudet L and Szabó C. Nitrosative stress and pharmacological modulation of heart failure. In press: Trends in Pharmacological Sciences 2005, in press.
8. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 2004; 555(Pt 3): 589-606.
9. Drexler H, Hornig B. Importance of endothelial function in chronic heart failure. J Cardiovasc Pharmacol 1996; 27 Suppl 2: S9-12.
10. Sun D, Huang A, Zhao G, Bernstein R, Forfia P, Xu X, et al. Reduced NO-dependent arteriolar dilation during the development of cardiomyopathy. Am J Physiol Heart Circ Physiol 2000; 278(2): H461-8.
11. Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002; 106(24): 3073-8.
12. Colombo PC, Banchs JE, Celaj S, Talreja A, Lachmann J, Malla S, et al. Endothelial cell activation in patients with decompensated heart failure. Circulation 2005; 111(1): 58-62.
13. Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol 2004; 287(5): R1014-30.
14. Fischer D, Rossa S, Landmesser U, Spiekermann S, Engberding N, Hornig B, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005; 26(1): 65-9.
15. Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, Nadal-Ginard B, et al. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 2001; 89(3): 279-86.
16. Polidori MC, Savino K, Alunni G, Freddio M, Senin U, Sies H, et al. Plasma lipophilic antioxidants and malondialdehyde in congestive heart failure patients: relationship to disease severity. Free Radic Biol Med 2002; 32(2): 148-52.
17. Polidori MC, Pratico D, Savino K, Rokach J, Stahl W, Mecocci P. Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. J Card Fail 2004; 10(4): 334-8.
18. Nakamura K, Kusano KF, Matsubara H, Nakamura Y, Miura A, Nishii N, et al. Relationship between oxidative stress and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Card Fail 2005; 11(2): 117-23.
19. Granger DN, Rutili G, McCord JM. Superoxide radicals in feline intestinal ischemia. Gastroenterology 1981; 81(1): 22-9.
20. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312(3): 159-63.
21. MacGowan SW, Regan MC, Malone C, Sharkey O, Young L, Gorey TF, et al. Superoxide radical and xanthine oxidoreductase activity in the human heart during cardiac operations. Ann Thorac Surg 1995; 60(5):1289-93.
22. Xia Y, Zweier JL. Substrate control of free radical generation from xanthine oxidase in the postischemic heart. J Biol Chem 1995; 270(32): 18797-803.
23. Bergsland J, LoBalsamo L, Lajos P, Feldman MJ, Mookerjee B. Allopurinol in prevention of reperfusion injury of hypoxically stored rat hearts. J Heart Transplant 1987; 6(3):137-40.
24. Vinten-Johansen J, Chiantella V, Faust KB, Johnston WE, McCain BL, Hartman M, et al. Myocardial protection with blood cardioplegia in ischemically injured hearts: reduction of reoxygenation injury with allopurinol. Ann Thorac Surg 1988; 45(3): 319-26.
25. Coghlan JG, Flitter WD, Clutton SM, Panda R, Daly R, Wright G, et al. Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994; 107(1): 248-56.
26. Castelli P, Condemi AM, Brambillasca C, Fundaro P, Botta M, Lemma M, et al. Improvement of cardiac function by allopurinol in patients undergoing cardiac surgery. J Cardiovasc Pharmacol 1995; 25(1): 119-25.
27. Akizuki S, Yoshida S, Chambers DE, Eddy LJ, Parmley LF, Yellon DM, et al. Infarct size limitation by the xanthine oxidase inhibitor, allopurinol, in closed-chest dogs with small infarcts. Cardiovasc Res 1985; 19(11): 686-92.
28. Ferdinandy P, Panas D, Schulz R. Peroxynitrite contributes to spontaneous loss of cardiac efficiency in isolated working rat hearts. Am J Physiol 1999; 276(6 Pt 2): H1861-7.
29. Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 2000; 87(3): 241-7.
30. Ekelund UE, Harrison RW, Shokek O, Thakkar RN, Tunin RS, Senzaki H, et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 1999; 85(5): 437-45.
31. Saavedra WF, Paolocci N, St John ME, Skaf MW, Stewart GC, Xie JS, et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 2002; 90(3): 297-304.
32. de Jong JW, Schoemaker RG, de Jonge R, Bernocchi P, Keijzer E, Harrison R, et al. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol 2000, 32(11): 2083-9.
33. Ukai T, Cheng CP, Tachibana H, Igawa A, Zhang ZS, Cheng HJ, et al. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. Circulation 2001; 103(5): 750-5.
34. Khan SA, Lee K, Minhas KM, Gonzalez DR, Raju SV, Tejani AD, et al. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc Natl Acad Sci U S A 2004; 101(45): 15944-8.
35. Bonaventura J, Gow A. NO and superoxide: opposite ends of the seesaw in cardiac contractility. Proc Natl Acad Sci USA 2004; 101(47): 16403-4.
36. Kogler H, Fraser H, McCune S, Altschuld R, Marban E. Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Cardiovasc Res 2003; 59(3): 582-92.
37. Stull LB, Leppo MK, Szweda L, Gao WD, Marban E. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res 2004; 95(10): 1005-11.
38. Engberding N, Spiekermann S, Schaefer A, Heineke A, Wiencke A, Muller M, et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation. 2004; 110(15): 2175-9.
39. Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998; 19(12): 1814-22.
40. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001; 104(20): 2407-11.
41. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107(15): 1991-7.
42. Doehner W, Anker SD. Uric acid in chronic heart failure. Semin Nephrol. 2005; 25(1): 61-6.
43. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106(2): 221-6.
44. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomball J, MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002; 87(3): 229-34.
45. Shehab AM, Butler R, MacFadyen RJ, Struthers AD. A placebo-controlled study examining the effect of allopurinol on heart rate variability and dysrhythmia counts in chronic heart failure. Br J Clin Pharmacol. 2001; 51(4): 329-34.
46. Freudenberger RS, Schwarz RP Jr, Brown J, Moore A, Mann D, Givertz MM, et al. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III - IV congestive heart failure. Expert Opin Investig Drugs 2004; 13(11): 1509-16.
47. Li JM, Gall NP, Grieve DJ, Chen M, Shah AM. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension. 2002; 40(4): 477-84.
48. Takayama T, Wada A, Tsutamoto T, Ohnishi M, Fujii M, Isono T, et al. Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor. Circ J 2004; 68(11): 1067-75.
49. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003; 41(12): 2164-71.
50. Linke A, Recchia F, Zhang X, Hintze TH. Acute and chronic endothelial dysfunction: implications for the development of heart failure. Heart Fail Rev 2003; 8(1): 87-97.
51. Trochu JN, Mital S, Zhang X, Xu X, Ochoa M, Liao JK, et al. Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res 2003; 60(2): 250-8.
52. Mital S, Barbone A, Addonizio LJ, Quaegebeur JM, Mosca RJ, Oz MC, et al. Endogenous endothelium-derived nitric oxide inhibits myocardial caspase activity: implications for treatment of end-stage heart failure. J Heart Lung Transplant 2002; 21(5): 576-85.
53. Adler S, Huang H, Trochu JN, Xu X, Gupta S, Hintze TH. Simvastatin reverses impaired regulation of renal oxygen consumption in congestive heart failure. Am J Physiol Renal Physiol. 2001 Nov;281(5): F802-9.
54. Recchia FA. Role of nitric oxide in the regulation of substrate metabolism in heart failure. Heart Fail Rev. 2002 Apr;7(2):141-8.
55. Tada H, Thompson CI, Recchia FA, Loke KE, Ochoa M, Smith CJ, et al. Myocardial glucose uptake is regulated by nitric oxide via endothelial nitric oxide synthase in Langendorff mouse heart. Circ Res 2000; 86(3): 270-4.
56. Recchia FA, McConnell PI, Bernstein RD, Vogel TR, Xu X, Hintze TH. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res 1998; 83(10): 969-79.
57. Kinugawa S, Huang H, Wang Z, Kaminski PM, Wolin MS, Hintze TH. A defect of neuronal nitric oxide synthase increases xanthine oxidase-derived superoxide anion and attenuates the control of myocardial oxygen consumption by nitric oxide derived from endothelial nitric oxide synthase. Circ Res 2005; 96(3): 355-62.
58. Li W, Mital S, Ojaimi C, Csiszar A, Kaley G, Hintze TH. Premature death and age-related cardiac dysfunction in male eNOS-knockout mice. J Mol Cell Cardiol 2004; 37(3): 671-80.
59. Walsh EK, Huang H, Wang Z, Williams J, de Crom R, van Haperen R, et al. Control of myocardial oxygen consumption in transgenic mice overexpressing vascular eNOS. Am J Physiol Heart Circ Physiol 2004; 287(5): H2115-21.
60. Adler A, Huang H, Wang Z, Conetta J, Levee E, Zhang X, et al. Endocardial endothelium in the avascular frog heart: role for diffusion of NO in control of cardiac O2 consumption. Am J Physiol Heart Circ Physiol 2004; 287(1): H14-21.
61. Hintze TH. Prologue: Nitric oxide-hormones, metabolism, and function. Am J Physiol Heart Circ Physiol 2001; 281(6): H2253-5.
62. Trochu JN, Bouhour JB, Kaley G, Hintze TH. Role of endothelium-derived nitric oxide in the regulation of cardiac oxygen metabolism: implications in health and disease. Circ Res 2000; 87(12): 1108-17.
63. Zhao G, Bernstein RD, Hintze TH. Nitric oxide and oxygen utilization: exercise, heart failure and diabetes. Coron Artery Dis 1999;10(5): 315-20.
64. Wolin MS, Xie YW, Hintze TH. Nitric oxide as a regulator of tissue oxygen consumption. Curr Opin Nephrol Hypertens 1999; 8(1): 97-103.
65. Xie YW, Shen W, Zhao G, Xu X, Wolin MS, Hintze TH. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro. Implications for the development of heart failure. Circ Res 1996; 79(3): 381-7.
66. Massion PB, Feron O, Dessy C, Balligand JL. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res 2003; 93(5): 388-98.
67. Paulus WJ, Bronzwaer JG. Nitric oxide's role in the heart: control of beating or breathing? Am J Physiol Heart Circ Physiol 2004; 287(1): H8-13.
68. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271(5 Pt 1): C1424-37.
69. Mihm MJ, Coyle CM, Schanbacher BL, Weinstein DM, Bauer JA. Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc Res 2001; 49(4): 798-807.
70. Feng Q, Lu X, Jones DL, Shen J, Arnold JM. Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 2001; 104(6): 700-4.
71. Chen Y, Traverse JH, Du R, Hou M, Bache RJ. Nitric oxide modulates myocardial oxygen consumption in the failing heart. Circulation 2002; 106(2): 273-9.
72. Funakoshi H, Kubota T, Kawamura N, Machida Y, Feldman AM, Tsutsui H, et al. Disruption of inducible nitric oxide synthase improves beta-adrenergic inotropic responsiveness but not the survival of mice with cytokine-induced cardiomyopathy. Circ Res 2002; 90(9): 959-65.
73. Kobayashi N, Horinaka S, Mita S, Yoshida K, Honda T, Kobayashi T, et al. Aminoguanidine inhibits mitogen-activated protein kinase and improves cardiac performance and cardiovascular remodeling in failing hearts of salt-sensitive hypertensive rats. J Hypertens 2002; 20(12): 2475-85.
74. Mungrue IN, Stewart DJ, Husain M. The Janus faces of iNOS. Circ Res 2003; 93(7): e74.
75. Vanderheyden M, Bartunek J, Knaapen M, Kockx M, De Bruyne B, Goethals M. Hemodynamic effects of inducible nitric oxide synthase and nitrotyrosine generation in heart failure. J Heart Lung Transplant 2004; 23(6): 723-8.
76. Ferreiro CR, Chagas AC, Carvalho MH, Dantas AP, Scavone C, Souza LC, et al. Expression of inducible nitric oxide synthase is increased in patients with heart failure due to ischemic disease. Braz J Med Biol Res 2004; 37(9): 1313-20.
77. Yang B, Larson DF, Watson RR. Modulation of iNOS activity in age-related cardiac dysfunction. Life Sci 2004; 75(6): 655-67.
78. Colombo PC, Banchs JE, Celaj S, Talreja A, Lachmann J, Malla S, et al. Endothelial cell activation in patients with decompensated heart failure. Circulation 2005; 111(1): 58-62.
79. Mungrue IN, Gros R, You X, Pirani A, Azad A, Csont T, et al. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest 2002; 109(6): 735-43.
80. Heger J, Godecke A, Flogel U, Merx MW, Molojavyi A, Kuhn-Velten WN, et al. Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ Res 2002; 90(1): 93-9.
81. Gealekman O, Abassi Z, Rubinstein I, Winaver J, Binah O. Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. Circulation 2002;105(2): 236-43.
82. Jones SP, Greer JJ, Ware PD, Yang J, Walsh K, Lefer DJ. Deficiency of iNOS does not attenuate severe congestive heart failure in mice. Am J Physiol Heart Circ Physiol 2005; 288(1): H365-70.
83. Damy T, Ratajczak P, Shah AM, Camors E, Marty I, Hasenfuss G, et al. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 2004; 363(9418): 1365-7.
84. Dai ZK, Tan MS, Chai CY, Yeh JL, Chou SH, Chiu CC, et al. Upregulation of endothelial nitric oxide synthase and endothelin-1 in pulmonary hypertension secondary to heart failure in aorta-banded rats. Pediatr Pulmonol 2004; 37(3): 249-56.
85. Turko IV, Murad F. Protein nitration in cardiovascular diseases. Pharmacol Rev 2002; 54(4): 619-34.
86. Szabo C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett 2003; 140-141: 105-12.
87. Virag L, Szabo E, Gergely P, Szabo C. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol Lett2003; 140-141: 113-24.
88. Hausladen A, Fridovich I. Superoxide and peroxynitrite inactivate aconitases, but nitric oxide does not. J Biol Chem 1994; 269(47): 29405-8.
89. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002; 54(3): 375-429.
90. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virag L, et al. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 2003; 107(6): 896-904.
91. Bianchi C, Wakiyama H, Faro R, Khan T, McCully JD, Levitsky S, Szabo C, Sellke FW. A novel peroxynitrite decomposer catalyst (FP-15) reduces myocardial infarct size in an in vivo peroxynitrite decomposer and acute ischemia-reperfusion in pigs. Ann Thorac Surg 2002; 74(4): 1201-7.
92. Szabo C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, et al. Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 2002; 8(10): 571-80.
93. Pacher P, Obrosova IG, Mabley JG, Szabo C. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr Med Chem 2005; 12(3): 267-75.
94. Szabo G, Liaudet L, Hagl S, Szabo C. Poly(ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovasc Res 2004; 61(3): 471-80.
95. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ Res 2001; 89(8): 684-91.
96. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E, Szabo C. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 2002; 51(2): 514-21.
97. Pacher P, Liaudet L, Mabley J, Komjati K, Szabo C. Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol 2002; 40(5): 1006-16.
98. Pacher P, Mabley JG, Soriano FG, Liaudet L, Szabo C. Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging. Int J Mol Med 2002; 9(6): 659-64.
99. Pacher P, Mabley JG, Soriano FG, Liaudet L, Komjati K, Szabo C. Endothelial dysfunction in aging animals: the role of poly(ADP-ribose) polymerase activation. Br J Pharmacol 2002; 135(6): 1347-50.
100. Pacher P, Mabley JG, Liaudet L, Evgenov OV, Marton A, Hasko G, et al. Left ventricular pressure-volume relationship in a rat model of advanced aging-associated heart failure. Am J Physiol Heart Circ Physiol 2004; 287(5): H2132-7.
101. Pacher P, Vaslin A, Benko R, Mabley JG, Liaudet L, Hasko G, et al. A new, potent poly(ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging. J Pharmacol Exp Ther 2004; 311(2): 485-91.
102. Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, Hasko G, et al. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 2002; 300(3): 862-7.
103. Bai P, Mabley JG, Liaudet L, Virag L, Szabo C, Pacher P. Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. Oncol Rep 2004; 11(2): 505-8.
104. Szenczí O, Kemecsei P, Holthuijsen MF, van Riel NA, van der Vusse GJ, Pacher P, et al. Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure. Biochem Pharmacol 2005; 69(5): 725-32.
105. Pacher P, Cziraki A, Mabley JG, Liaudet L, Papp L, Szabo C. Role of poly(ADP-ribose) polymerase activation in endotoxin-induced cardiac collapse in rodents. Biochem Pharmacol 2002; 64(12): 1785-91.
106. Pillai JB, Russell HM, Raman J, Jeevanandam V, Gupta MP. Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure. Am J Physiol Heart Circ Physiol 2005; 288(2): H486-96.
107. Xiao CY, Chen M, Zsengeller Z, Li H, Kiss L, Kollai M, et al. Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. J Pharmacol Exp Ther 2005; 312(3): 891-8.
108. El Alaoui-Talibi Z, Guendouz A, Moravec M, Moravec J. Control of oxidative metabolism in volume-overloaded rat hearts: effect of propionyl-L-carnitine. Am J Physiol 1997; 272(4 Pt 2): H1615-24.
109. Ungvari Z, Csiszar A, Kaminski PM, Wolin MS, Koller A. Chronic high pressure-induced arterial oxidative stress: involvement of protein kinase C-dependent NAD(P)H oxidase and local renin-angiotensin system. Am J Pathol 2004; 165(1): 219-26.
110. Lei B, Lionetti V, Young ME, Chandler MP, d'Agostino C, Kang E, et al. aradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol 2004; 36(4): 567-76.
111. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002; 297(5579): 259-63.
112. Du L, Zhang X, Han YY, Burke NA, Kochanek PM, Watkins SC, et al. Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress. J Biol Chem 2003; 278(20): 18426-33.
113. Chen M, Zsengeller Z, Xiao CY, Szabo C. Mitochondrial-to-nuclear translocation of apoptosis-inducing factor in cardiac myocytes during oxidant stress: potential role of poly(ADP-ribose) polymerase-1. Cardiovasc Res 2004; 63(4): 682-8.
114. Xiao CY, Chen M, Zsengeller Z, Szabo C. Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor. J Pharmacol Exp Ther 2004; 310(2): 498-504.
115. Wattanapitayakul SK, Weinstein DM, Holycross BJ, Bauer JA. Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders. FASEB J 2000; 14(2): 271-8.
116. Mihm MJ, Wattanapitayakul SK, Piao SF, Hoyt DG, Bauer JA. Effects of angiotensin II on vascular endothelial cells: formation of receptor-mediated reactive nitrogen species. Biochem Pharmacol 2003; 65(7): 1189-97.
117. Szabo C, Pacher P, Zsengeller Z, Vaslin A, Komjati K, Benko R, Chen M, Mabley JG, Kollai M. Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. Mol Med 2004; 10(1-6): 28-35.
118. Minchenko AG, Stevens MJ, White L, Abatan OI, Komjati K, Pacher P, et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J 2003; 17(11): 1514-6.
119. Gupte SA, Arshad M, Viola S, Kaminski PM, Ungvari Z, Rabbani G, et al. Pentose phosphate pathway coordinates multiple redox-controlled relaxing mechanisms in bovine coronary arteries. Am J Physiol Heart Circ Physiol 2003; 285(6): H2316-26.
120. Gupte SA, Kaminski PM, Floyd B, Agarwal R, Ali N, Ahmad M, et al. Cytosolic NADPH may regulate differences in basal Nox oxidase-derived superoxide generation in bovine coronary and pulmonary arteries. Am J Physiol Heart Circ Physiol 2005; 288(1): H13-21.